

Adriamycin® regimens extend survival in disseminated breast cancer

Survival advantage of Adriamycin proven in comparative studies¹⁻⁴

Median Survival (months)	
Tormey¹ (1984)	CMFVP (n = 109) 13
	CAFVP (n = 107) 19 (p = 0.01)
Aisner² (1981)	CMF (n = 96) 14
	CAF (n = 80) 24 (p = 0.02)
Bull³ (1978)	CMF (n = 40) 17
	CAF (n = 38) 27
Muss⁴ (1978)	CMFVP (n = 72) 20
	CAFVP (n = 76) 33 (p = 0.07)
Months	10 20 30

Abbreviations: A, ADRIAMYCIN; C, cyclophosphamide; M, methotrexate; F, 5-fluorouracil; V, vincristine; P, prednisone.

- Substituting Adriamycin for methotrexate dramatically improved survival; this improvement correlated with better response rates¹⁻⁴
- Adriamycin regimens were first-line chemotherapy for most patients^{1,3,4}
- Projected total Adriamycin dose ranged from 300 mg/m² to 500 mg/m²^{1,3,4}